Cerevance’s human element
How Cerevance’s platform identifies circuit-specific CNS targets
Cerevance Inc. plans to treat neurological diseases by rebalancing disrupted neuronal circuits. The company is identifying circuit-specific neurological targets via its NETSeq RNA profiling platform, and thinks its ability to start with human tissue will translate better to the clinic than platforms based on preclinical animal models.
NETSeq has yielded eight programs in the last two years. Lead program CVN058 is in Phase Ib testing to treat cognitive impairment in schizophrenia, and Cerevance plans to submit an IND next month on symptomatic Parkinson’s disease therapy candidate CVN424, which has greater circuit-specificity than SOC and may reduce the dyskinesia side effect. Preclinical programs include additional compounds for PD, neuroinflammation in Alzheimer’s disease, Rett syndrome, and anxiety and addiction. ...